Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism

European Journal of Clinical Pharmacology

Volumn 66, Issue 11, 2010, Pages 1131-1136

  Shi, Hui Yan ^a   Yan, Jin ^a   Zhu, Wen Hui ^a   Yang, Guo Ping ^a   Tan, Zhi Rong ^a   Wu, Wei Hua ^a   Zhou, Gan ^a   Chen, Xiao Ping ^a   Ouyang, Dong Sheng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Chinese; CYP2C19; Erythromycin; Genetic polymorphism; Voriconazole

Indexed keywords

CYTOCHROME P450 2C19; ERYTHROMYCIN; PLACEBO; VORICONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENTIATION; DRUG WITHDRAWAL; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; ERYTHROMYCIN; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN SYNTHESIS INHIBITORS; PYRIMIDINES; TRIAZOLES; YOUNG ADULT;

EID: 78649320149     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0869-3     Document Type: Article

References (30)

1. DJ Sheehan CA Hitchcock CM Sibley 1999 Current and emerging azole antifungal agents Clin Microbiol Rev 12 1 40 79 1:CAS:528:DyaK1MXpvVOlsw%3D%3D 9880474
2. PH Chandrasekar E Manavathu 2001 Voriconazole: a second-generation triazole Drugs Today (Barc) 37 2 135 148 1:CAS:528:DC%2BD3MXjtFKgu7o%3D
3. MA Ghannoum DM Kuhn 2002 Voriconazole-better chances for patients with invasive mycoses Eur J Med Res 7 5 242 256 1:CAS:528:DC%2BD38Xltlamsb8%3D 12069915
4. HL Hoffman RC Rathbun 2002 Review of the safety and efficacy of voriconazole Expert Opin Investig Drugs 11 3 409 429 1:CAS:528: DC%2BD38XitFCmurY%3D 10.1517/13543784.11.3.409 11866669 (Pubitemid 34213394)
5. R Herbrecht DW Denning TF Patterson JE Bennett RE Greene JW Oestmann, et al. 2002 Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 6 408 415 1:CAS:528:DC%2BD38XlvFKrt7o%3D 10.1056/NEJMoa020191 12167683 (Pubitemid 34851833)
6. JR Perfect KA Marr TJ Walsh RN Greenberg B DuPont J de la Torre-Cisneros, et al. 2003 Voriconazole treatment for less-common, emerging, or refractory fungal infections Clin Infect Dis 36 9 1122 1131 1:CAS:528:DC%2BD3sXksFSgtb4%3D 10.1086/374557 12715306 (Pubitemid 36549632)
7. MA Pfaller DJ Diekema JH Rex A Espinel-Ingroff EM Johnson D Andes, et al. 2006 Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints J Clin Microbiol 44 3 819 826 1:STN:280:DC%2BD287ivFOmtQ%3D%3D 10.1128/JCM.44.3.819- 826.2006 16517860
8. U Theuretzbacher F Ihle H Derendorf 2006 Pharmacokinetic/pharmacodynamic profile of voriconazole Clin Pharmacokinet 45 7 649 663 1:CAS:528: DC%2BD28Xot1eksL0%3D 10.2165/00003088-200645070-00002 16802848 (Pubitemid 43990568)
9. R Hyland BC Jones DA Smith 2003 Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole Drug Metab Dispos 31 5 540 547 1:STN:280:DC%2BD3s7psF2mtQ%3D%3D 10.1124/dmd.31.5.540 12695341 (Pubitemid 36444162)
10. N Murayama N Imai T Nakane M Shimizu H Yamazaki 2007 Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes Biochem Pharmacol 73 12 2020 2026 1:CAS:528:DC%2BD2sXkvFOjurY%3D 10.1016/j.bcp.2007.03. 012 17433262 (Pubitemid 46677908)
11. GR Wilkinson FP Guengerich RA Branch 1989 Genetic polymorphism of S-mephenytoin hydroxylation Pharmacol Ther 43 1 53 76 1:CAS:528: DyaL1MXlt1Khu7w%3D 10.1016/0163-7258(89)90047-8 2675129
12. ZS Xiao JA Goldstein HG Xie J Blaisdell W Wang CH Jiang, et al. 1997 Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele J Pharmacol Exp Ther 281 1 604 609 1:CAS:528:DyaK2sXislWjt7o%3D 9103550
13. XP Qin HG Xie W Wang N He SL Huang ZH Xu, et al. 1999 Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects Clin Pharmacol Ther 66 6 642 646 1:CAS:528:DC%2BD3cXlsVamtA%3D%3D 10613621
14. HH Zhou 2001 CYP2C19 genotype determines enzyme activity and inducibility of S- mephenytoin hydroxylase Clin Chim Acta 313 1-2 203 208 1:CAS:528:DC%2BD3MXnvFGqu74%3D 10.1016/S0009-8981(01)00696-9 11694260 (Pubitemid 33016712)
15. J Weiss MM Ten Hoevel J Burhenne I Walter-Sack MM Hoffmann J Rengelshausen WE Haefeli G Mikus 2009 CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole J Clin Pharmacol 49 2 196 204 1:CAS:528:DC%2BD1MXisFCisrc%3D 10.1177/0091270008327537 19033450
16. K Matsumoto K Ikawa K Abematsu N Fukunaga K Nishida T Fukamizu Y Shimodozono N Morikawa Y Takeda K Yamada 2009 Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes Int J Antimicrob Agents 34 1 91 94 1:CAS:528: DC%2BD1MXmsVShsro%3D 10.1016/j.ijantimicag.2009.01.008 19261446
17. L Jeu FJ Piacenti AG Lyakhovetskiy HB Fung 2003 Voriconazole Clin Ther 25 5 1321 1381 1:CAS:528:DC%2BD3sXlsFCmsbY%3D 10.1016/S0149-2918(03)80126-1 12867215 (Pubitemid 36677282)
18. Y Ikeda K Umemura K Kondo K Sekiguchi S Miyoshi M Nakashima 2004 Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status Clin Pharmacol Ther 75 6 587 588 1:CAS:528:DC%2BD2cXkslWmt7k%3D 10.1016/j.clpt.2004. 02.002 15179414 (Pubitemid 38746611)
19. J Rengelshausen M Banfield KD Riedel J Burhenne J Weiss T Thomsen, et al. 2005 Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics Clin Pharmacol Ther 78 1 25 33 1:CAS:528:DC%2BD2MXlvFKruro%3D 10.1016/j.clpt.2005.01.024 16003289 (Pubitemid 40956928)
20. S Zhou CS Yung B Cher Goh E Chan W Duan M Huang, et al. 2005 Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs Clin Pharmacokinet 44 279 304 1:CAS:528:DC%2BD2MXjs1Kru7o%3D 10.2165/00003088- 200544030-00005 15762770 (Pubitemid 40477790)
21. NE Nierenberg GR Thompson JS Lewis BK Hogan TF Patterson 2010 Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in patient receiving low-dose ritonavir Med Mycol 48 3 532 536 1:CAS:528:DC%2BC3cXkt1Khtrc%3D 10.3109/13693780903325282 19835489
22. P Periti T Mazzei E Mini A Novelli 1992 Pharmacokinetic drug interactions of macrolides Clin Pharmacokinet 23 2 106 131 1:CAS:528:DyaK38XlvVCju74%3D 10.2165/00003088-199223020-00004 1511528
23. NA Von Rosensteil D Adam 1995 Macrolide antibacterials. Drug interactions of clinical significance Drug Saf 13 2 105 122 10.2165/00002018-199513020-00005
24. C De Mey M Althaus E Ezan A Retzow 2001 Erythromycin increases plasma concentrations of alpha-dihydroergocryptine in humans Clin Pharmacol Ther 70 2 142 148 10.1067/mcp.2001.117286 11503008 (Pubitemid 32777766)
25. SM De Morais GR Wilkinson J Blaisdell K Nakamura UA Meyer JA Goldstein 1994 The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans J Biol Chem 269 22 15419 15422 8195181
26. SM De Morais JA Goldstein HG Xie SL Huang YQ Lu H Xia, et al. 1995 Genetic analysis of the S-mephenytoin polymorphism in a Chinese population Clin Pharmacol Ther 58 4 404 411 1:CAS:528:DyaK28XhslKrsg%3D%3D 10.1016/0009-9236(95) 90053-5 7586932
27. TI Edeki JA Goldstein SM de Morais L Hajiloo M Butler P Chapdelaine GR Wilkinson 1996 Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans Pharmacogenetics 6 4 357 360 1:CAS:528:DyaK28XlvFaqt70%3D 10.1097/00008571-199608000-00009 8873222
28. R Gage DA Stopher 1998 A rapid HPLC assay for voriconazole in human plasma J Pharm Biomed Anal 17 8 1449 1453 1:CAS:528:DyaK1cXmsFamurw%3D 10.1016/S0731-7085(98)00004-1 9800664 (Pubitemid 29027752)
29. L Purkins N Wood P Ghahramani D Kleinermans G Layton D Nichols 2003 No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers Br J Clin Pharmacol 56 Suppl 1 30 36 1:CAS:528:DC%2BD2cXjtFyhtQ%3D%3D 10.1046/j.1365-2125.2003. 01996.x 14616411
30. G Mikus V Schowel M Drzewinska J Rengelshausen R Ding KD Riedel, et al. 2006 Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir Clin Pharmacol Ther 80 2 126 135 1:CAS:528:DC%2BD28XotFKhsbY%3D 10.1016/j.clpt.2006.04.004 16890574 (Pubitemid 44160688)